Quidel Corporation (QDEL) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.069x

Based on the latest financial reports, Quidel Corporation (QDEL) has a cash flow conversion efficiency ratio of 0.069x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($131.90 Million) by net assets ($1.92 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Quidel Corporation - Cash Flow Conversion Efficiency Trend (1991–2025)

This chart illustrates how Quidel Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Quidel Corporation (QDEL) total liabilities for a breakdown of total debt and financial obligations.

Quidel Corporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Quidel Corporation ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Gryphon Capital Income Trust
AU:GCI
-0.161x
Imperial Metals Corporation
TO:III
0.073x
Shenyu Communication Technology Inc
SHE:300563
0.029x
Shandong Longhua New Material Co. Ltd.
SHE:301149
0.012x
Shilpa Medicare Limited
NSE:SHILPAMED
0.083x
Bergman & Beving AB (publ)
ST:BERG-B
0.065x
GL Events SA
PA:GLO
0.162x
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
N/A

Annual Cash Flow Conversion Efficiency for Quidel Corporation (1991–2025)

The table below shows the annual cash flow conversion efficiency of Quidel Corporation from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see QDEL stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $1.92 Billion $105.20 Million 0.055x +96.97%
2024-12-31 $2.98 Billion $83.00 Million 0.028x -50.32%
2023-12-31 $5.01 Billion $280.20 Million 0.056x -68.80%
2022-12-31 $4.93 Billion $885.30 Million 0.179x -57.05%
2021-12-31 $1.93 Billion $805.87 Million 0.418x -11.61%
2020-12-31 $1.33 Billion $629.76 Million 0.473x +96.71%
2019-12-31 $559.82 Million $134.49 Million 0.240x -25.02%
2018-12-31 $425.58 Million $136.34 Million 0.320x +162.58%
2017-12-31 $227.10 Million $27.71 Million 0.122x +107.18%
2016-12-31 $200.63 Million $11.81 Million 0.059x -64.53%
2015-12-31 $218.68 Million $36.31 Million 0.166x +14.00%
2014-12-31 $245.01 Million $35.69 Million 0.146x +26.91%
2013-12-31 $223.78 Million $25.68 Million 0.115x +16.78%
2012-12-31 $199.78 Million $19.63 Million 0.098x -61.22%
2011-12-31 $185.39 Million $46.98 Million 0.253x +377.04%
2010-12-31 $112.52 Million $-10.29 Million -0.091x -115.88%
2009-12-31 $126.45 Million $72.84 Million 0.576x +137.34%
2008-12-31 $119.24 Million $28.94 Million 0.243x -4.39%
2007-12-31 $107.70 Million $27.34 Million 0.254x +26.47%
2006-12-31 $103.28 Million $20.73 Million 0.201x +1333.11%
2005-12-31 $87.24 Million $1.22 Million 0.014x -87.30%
2004-12-31 $90.19 Million $9.95 Million 0.110x -47.38%
2003-12-31 $89.78 Million $18.82 Million 0.210x +113.65%
2002-12-31 $62.76 Million $6.16 Million 0.098x +0.91%
2001-12-31 $60.41 Million $5.87 Million 0.097x +213.93%
2000-12-31 $58.31 Million $1.81 Million 0.031x +69.20%
1999-12-31 $43.70 Million $800.00K 0.018x -54.54%
1998-12-31 $44.70 Million $1.80 Million 0.040x -77.82%
1997-12-31 $36.90 Million $6.70 Million 0.182x +22.91%
1996-12-31 $35.20 Million $5.20 Million 0.148x +279.66%
1995-12-31 $25.70 Million $1.00 Million 0.039x +829.96%
1994-12-31 $23.90 Million $100.00K 0.004x +131.10%
1993-12-31 $22.30 Million $-300.00K -0.013x -114.66%
1992-12-31 $10.90 Million $1.00 Million 0.092x +126.41%
1991-12-31 $9.50 Million $-3.30 Million -0.347x --

About Quidel Corporation

NASDAQ:QDEL USA Medical Devices
Market Cap
$860.55 Million
Market Cap Rank
#9807 Global
#2527 in USA
Share Price
$12.64
Change (1 day)
+2.76%
52-Week Range
$11.24 - $37.42
All Time High
$301.96
About

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laborator… Read more